Microsoft word - living with lupus.rtf
Acetylation/acetyltransferase, 153–154, 154
ACL (anti-cardiolipin), 95, 135–136, 174
ACR.
See American College of Rheumatology (ACR)
.
See also Osteonecrosis; Osteoporosis
American Academy of Orthpaedic Surgeons (AAOS),
diagnostic criteria, 20–21, 22–30, 200
ANA (antinuclear antibodies), 29–30, 151
Angio-tensin-converting-enzyme (ACE), 140
Centers for Disease Control and Prevention (CDC), 2,
Anti-inflammatory drugs.
See Corticosteroids
anti-cardiolipin (ACL), 95, 135–136, 174
psychological/emotional concerns, 207–209
anti-phospholipids (APLs), 32–33, 135–137
APLs (Anti-phospholids), 32–33, 135–137
Arthritis, 24–25, 32, 180–181, 199–200
Connie's story, 10–13, 65–66, 69, 75, 185, 186, 188
Arthritis Foundation, 61, 191, 221–222
Counseling, phsycological/psychiatric, 208–209
Eileen's story, 12–13, 32, 71–72, 86–88, 98, 185–186,
Elizabeth's story, 13–14, 27, 71, 167, 185, 186–187,
Emotional health, 69–70, 191–195, 207–209
Erythrocyte sedimentation rate (ESR), 31
additional signs, symptoms, tests, 30–34
antinuclear antibodies (ANA), 29–30, 151
Extractable nuclear antigens (ENA), 31–32
Diagnostic and Therapeutic Criteria Committee, 20
Eye, dry.
See Sjögren's syndrome
Dietary supplements.
See Supplements
Discoid lupus erythematosus (DLE).
See Discoid
Food and Drug Administration (FDA), 140, 156, 159–
.
See also Congenital heart block; Libman-Sacks
Drug-induced lupus.
See Lupus-like syndrome (LLS)
Drug-related lupus.
See Lupus-like syndrome (LLS)
silicone gel implant, precautions for, 161–163
HLA (histocompatibility) typing, 40–41, 103–105, 153
HTLV (human T-cell lymphotropic virus), 48
Human immunodeficiency virus.
See AIDS
Hydralazine/Hydrazine, 152, 154, 155, 166, 169
Hydroxychloroquine, 75–76, 78, 143–144, 201
Mouth, dry.
See Sjögren's syndrome
Immune thrombocytopenia (ITP), 26, 94–95, 136
Immunosuppressants, 80–82, 201, 202, 204
International Human Renal Transplant Registry, 103
Nancy's story, 16–17, 69, 71, 75, 90, 187, 189
ITP (immune thrombocytopenia), 26, 94–95, 136
National Institutes of Health (NIH), 50, 81–82, 111–
Jan's story, 14–15, 24–25, 56–57, 69, 91, 167, 187,
Nephritis, nephrosis, nephrotic syndrome, 100
Joint disease.
See Arthritis; Osteonecrosis
Nonsteroidal anti-inflammatory drugs.
See NSAIDs
Kidney disease, 26, 32, 90–91, 99–105
Light sensitivity.
See Photosensitivity
alternative/additional medicine, 116–118
Lisa's story, 15–16, 69, 76, 97, 98, 171, 221
Lupus Foundation of America (LFA), 61, 222
Patient/doctor relationship.
See Doctor/patient
Raynaud's syndrome.
See Raynaud's phenomenon
Renal disease, 26, 32, 90–91, 99–105
Photosensitivity, 23–24, 54–55, 170–173, 201–202
Physician.
See Doctor/patient relationship
Seizures.
See Neurologic disorder
Silicone gel implants.
See Breast implants
Sjögren's syndrome, 32, 49, 156–157, 175–177
Premature childbirth, 112, 133–134, 145–146
President's Council on Physical Fitness, 120–131
SSPE (subacute sclerosing panencephalitis), 51–52
Raynaud's disease.
See Raynaud's phenomenon
T T-cells, 48, 49–50 Tai chi, 193 Tamoxifen, 183, 215–216 Tartrazine, 166, 173 Teens.
See Children and teens Tendon rupture, 98 Thorazine, 152 Throat sores, 24 Thrombocytopenia, 26, 94–95, 136 Thrombophlebitis, 12 Thyrocalcitonin, 116 Tolmetin, 80 Total lymphoid irradiation (TLI), 213–214 Toxemia of pregnancy, 141–142 Treatment plan, 63–65
.
See also Corticosteroids; Drug therapy
Triamcinolone, 88, 91 Tripterygium wilfordii, 217 Tubal ligation, 148 Twins, 39–40, 198–199 U Ulcers, 24, 180 Uniform Anatomical Gift Act, 104 United Network for Organ Sharing, 103 Uremia, 100 V Vaccinations.
See Immunizations Varicella.
See Chicken pox Varicella-zoster virus (VZV), 46, 99 Vasospasm, 82 Verrucous endocarditis, 174–175 Virus, 45–54, 98–99 Vitamin A, 115 Vitamin D, 114 VZIG (varicella-zoster immune globulin), 205–206 W Weight, 92, 199 Z Zantac, 79 Zinc, 115 Zocor, 153 Zorivax, 99, 206
Source: http://lakeshoreindexing.com/yahoo_site_admin/assets/docs/Living_with_Lupus.19120016.pdf
Estatutos de Befesa Medio Ambiente, S.A. Artículo 3.- Traslado de domicilio. Acuerdo de la Junta General Ordinaria de Accionistas de 17 de abrilArtículo 5- Texto vigente aprobado según acuerdo de la Junta General Ordinaria del 21 de junio deArtículos 6, 8, 11, 12, 13, 14, 15 18, 23 y 24 Texto vigente según Decisión del Accionista Único deArtículo 17.- Texto vigente aprobado según
CHAMPIONNAT NATIONAL Show affilié à l'European Arab Horse Show Commission sous le n° 256-2013/MO RESULTATS DU SHOW CHAMPIONNAT NATIONAL Classe 1 JURY CLASSES Poulains de 1 an Dr MAREK TRELA Dr TON HULSHOF Dr NASHAAT HEGAZY Dr ABDERAZZAK HMIDANI Dr ABDELOUAHED MAAGOUL Dr MOHAMED OUSSIDHOUM Nom Cheval Date naissance Nom et prènom CHAMPIO
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z |
0-9 |